GenNext Technologies, a growth-stage company that provides instrumentation, software, and services to pharmaceutical researchers, was awarded the 2022 Grand Prize Award in the BioTools Innovator competition.

BioTools Innovator is the largest life science accelerator in the world, supported by founding partners Research Corporation Technologies and BroadOak Capital Partners. GenNext, chosen amongst a field of 160 emerging life science tools companies, will receive US$250K in non-dilutive funding, along with access to an elite ecosystem of mentors, peers, and investors to help ensure the continued growth of GenNext Technologies and the success of its
customers in biopharmaceutical discovery and development.

Scot Weinberger, CEO of GenNext Technologies, commented: “Not only did we gain $250,000 in non-dilutive funding, but BioTools has and will continue to open the doors to an elite group of mentors, partners, and investors over the months and years to come.

“This accolade further establishes GenNext as a true rising star in the life science tools space. This BioTools experience has given us a platform to convey our mission and value to BioPharma, and we are proud to say that GenNext is here to transform how researchers perform protein therapeutic Higher Order Structure (HOS) analysis using our novel Hydroxyl Radical Protein Footprinting (HRPF) tools, resulting in more effective and safer biopharmaceuticals.”  GenNext is addressing an important unmet need with its novel Flash Oxidation (Fox) Protein Footprinting System comprised of instrumentation, consumables, software, and services for biopharmaceutical researchers investigating protein structure, interactions, folding, aggregation, formulation, and delivery.